文献速递淋巴瘤白血病

CD49d与慢性淋巴细胞白血病患者淋巴结表现及随后发生淋巴结病的相关性

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2017-04-07

研究纳入797例新诊断慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,279例(35%)CD49d阳性(≥30% CLL细胞表达)。CD49d阳性与淋巴结病表现相关(OR 2.51,95%CI 1.64-3.83,P<0.001);在Rai 0期患者中,CD49d阳性与淋巴结病发生时间缩短相关(3.2年 vs 未达到,P<0.01)。

要点

  • CD49d阳性定义为≥30% CLL细胞表达,797例中279例(35%)为阳性。
  • CD49d阳性患者更常见淋巴结病表现,校正FISH和IGHV后OR 2.51(95%CI 1.64-3.83,P<0.001)。
  • Rai 0期CD49d阳性者淋巴结病发生时间缩短(3.2年 vs 未达到,P<0.01)。

核心结论

  • CD49d阳性CLL患者病程以淋巴结病为主导,此发现可能对治疗选择和疾病监测有启示。

研究设计与样本

  • 研究纳入797例新诊断CLL/SLL患者,通过流式细胞术检测CD49d表达,≥30% CLL细胞表达定义为阳性。

主要发现

  • 797例中279例(35%)为CD49d阳性;CD49d阳性患者更常见淋巴结病表现(P<0.001),校正FISH和IGHV突变状态后OR 2.51(95%CI 1.64-3.83,P<0.001)。
  • 在CLL Rai 0期患者中,CD49d阳性与淋巴结病发生时间较短相关(3.2年 vs 未达到,P<0.01)。
  • 分别校正FISH(HR 2.18,95%CI 1.25-3.81,P=0.006)或IGHV状态(HR 2.02,95%CI 1.11-3.69,P=0.02)后关联仍存在,但同时校正两者后关联减弱(HR 1.72,95%CI 0.88-3.38,P=0.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD49d is a surface integrin that is expressed on chronic lymphocytic leukaemia (CLL) cells, and strongly correlates with more aggressive disease. Given its association with cell-cell adhesion and leucocyte trafficking, we hypothesized that patients with high CD49d expression would experience a clinical course dominated by lymphadenopathy. CD49d expression was measured by flow cytometry and considered positive if expressed by ≥30% of CLL cells. The study included 797 newly diagnosed CLL/small lymphocytic leukaemia patients; 279 (35%) were CD49d positive. CD49d-positive patients were more likely to present with lymphadenopathy (P < 0·001); a finding that persisted after adjusting for fluorescence in situ hybridisation (FISH) and IGHV mutation status [odds ratio (OR) 2·51; 95% confidence interval (CI) 1·64-3·83; P < 0·001]. Among CLL Rai 0 patients, CD49d positivity was associated with shorter time to development of lymphadenopathy (3·2 years vs not reached, P < 0·01). This association was maintained after adjusting for either FISH [hazard ratio (HR) 2·18; 95% CI 1·25-3·81; P = 0·006) or IGHV status (HR 2·02; 95% CI 1·11-3·69; P = 0·02) individually, but was attenuated when adjusting by both (HR 1·72; 95% CI 0·88-3·38; P = 0·11).These data demonstrate that CD49d-positive CLL patients experience a disease course dominated by lymphadenopathy. These findings could have implications for therapy selection and disease monitoring.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Strati P, Parikh SA, Chaffee KG, et al. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017. PMID: 28386906. doi:10.1111/bjh.14647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。